ALGS Latest Press Releases

-- October 5, 2026 --

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting 2026 Globe Newswire 4:05 PM

-- September 2, 2026 --

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference Globe Newswire 8:00 AM

-- August 12, 2026 --

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China Globe Newswire 4:05 PM

-- August 6, 2026 --

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- July 30, 2026 --

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 Globe Newswire 8:00 AM

-- July 13, 2026 --

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection Globe Newswire 8:00 AM

-- July 6, 2026 --

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection Globe Newswire 4:05 PM

-- May 27, 2026 --

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 Globe Newswire 2:30 AM

-- May 13, 2026 --

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 Globe Newswire 2:05 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software